Rajiv De Silva
Rajiv De Silva is President, Chief Executive Officer and a Director of Endo. Prior to joining Endo in March 2013, Mr. De Silva served as the President of Valeant Pharmaceuticals International, Inc. from October 2010 to January 2013 and served as its Chief Operating Officer, Specialty Pharmaceuticals from January 2009 until January 2013. He was responsible for all specialty pharmaceutical operations, including sales and marketing, research and development, manufacturing and business development. He has broad international experience, having managed businesses in the United States, Europe, Canada, Latin America, Asia, South Africa and Australia/New Zealand. Prior to joining Valeant, Mr. De Silva held various leadership positions with Novartis. He served as President of Novartis Vaccines USA and Head, Vaccines of the Americas at Novartis. During this time, he played a key leadership role at Novartis' Vaccines & Diagnostics Division. Mr. De Silva also served as President of Novartis Pharmaceuticals Canada. He originally joined Novartis as Global Head of Strategic Planning for Novartis Pharma AG in Basel, Switzerland. Prior to his time at Novartis, Mr. De Silva was a Principal at McKinsey & Company and served as a member of the leadership group of its Pharmaceuticals and Medical Products Practice. Mr. De Silva was a Director of AMAG Pharmaceuticals, Inc. and is currently a Member of the Board of Trustees at Kent Place School in Summit, NJ. He holds a Bachelor of Science in Engineering, Honors from Princeton University, and a Master of Science from Stanford University and a Master of Business Administration with Distinction from the Wharton School at the University of Pennsylvania.
Don DeGolyer, Chief Operating Officer of Pharmaceuticals, joined Endo in August 2013. In this role, he leads both the Qualitest and Endo Pharmaceuticals businesses as fully integrated business units. Prior to joining Endo, Mr. DeGolyer served as President of Sandoz Inc. (a Novartis company) the second largest generics company in the world. While at Novartis, Mr. DeGolyer held various senior leadership positions including, US Managed Markets, Established Medicines for Novartis Pharmaceuticals and was a member of the Executive Committee. Prior to Novartis, Mr. DeGolyer held positions of increasing responsibilities with Johnson and Johnson for 11 years in pharmaceutical commercial roles including senior leadership positions in marketing and sales. Additionally, Mr. DeGolyer has international pharmaceutical experience and health information technology expertise, having held senior leadership roles at Oxford GlycoSciences Plc and ParkStone Medical, respectively. He began his career at Pfizer in sales and sales management. Mr. DeGolyer served as Vice Chairman on the Executive Committee and Board of Directors for the Generic Pharmaceutical Association (GPhA). He holds a Masters of Business Administration from Fairleigh Dickinson University and is a graduate of University of Rochester.
Camille Farhat joined Endo in September 2012 as President of AMS, a world leader in developing and delivering medical devices and procedures to treat patients with pelvic health conditions. Mr. Farhat brings broad global experience from assignments in 10 countries and nine industries over 22 years. He is a business executive with a track record of revitalizing, turning around, and profitably growing businesses. Before joining Endo, Mr. Farhat held the position of General Manager of Baxter Pharmaceuticals & Technologies (BPT). Camille joined Baxter in February 2006 as General Manager of Global Infusion Systems. Prior to Baxter, Mr. Farhat was with Medtronic where he held the position of Vice President of Business Development after he was Global General Manager of Medtronic’s Gastroenterology and Urology division. He spent 13 years with General Electric (GE) where he gained broad executive experience with assignments in many businesses, geographies, and functional areas, leading up to his final role with the company as General Manager for the Computed Tomography (CT) business.
He holds a Master of Business Administration from Harvard University, a degree in European Union Studies from Institut National d’Etudes Politiques de Paris, and a Bachelor of Sciences (summa cum laude) in International Finance and Accounting from Northeastern University.
Susan Hall, Ph.D.
Susan Hall, Ph.D. joined Endo as Executive Vice President, Chief Scientific Officer and Global Head of Research and Development and Quality in March 2014. In this role, she leads branded pharmaceutical product development and R&D operations and has responsibility for company-wide scientific and quality matters. Prior to joining Endo, Dr. Hall served as Senior Vice President and Global Head of Research and Development at Valeant Pharmaceuticals International, Inc. with responsibility for the company's product pipeline, life cycle management activities, and Quality Compliance. Prior to joining Valeant, Dr. Hall held various management and leadership positions with Glaxo/GlaxoWellcome/GlaxoSmithKline, initially in the U.K. and then in the U.S., across the disciplines of Clinical Pharmacology, Project Management, Medical Affairs, Genomics and Regulatory Affairs. Dr. Hall commenced her pharmaceutical career with Beecham Pharmaceuticals in the Department of Drug Metabolism and Pharmacokinetics, based in the U.K. Dr. Hall holds a B.S. degree in Pharmacology from the University of Leeds (U.K.) and a Ph.D. in Pharmacokinetics from the Department of Pharmacy, University of Manchester (U.K.).
Caroline B. Manogue
Caroline B. Manogue has served as Executive Vice President, Chief Legal Officer since 2004. She also served as Corporate Secretary and was responsible for all corporate governance matters until 2014. Prior to joining Endo in 2000 as Endo’s Senior Vice President, General Counsel and Secretary, she practiced law in the New York office of the law firm Skadden, Arps, Slate, Meagher & Flom LLP, where she specialized in mergers & acquisitions, securities and corporate law. At Endo, she is responsible for all aspects of the company’s legal function, including securities law, litigation, intellectual property and commercial law, as well as overseeing compliance with current laws and existing pharmaceutical company guidelines relating to, among other things, clinical, sales and marketing practices. Ms. Manogue received her J.D. from Fordham Law School and her B.A. cum laude from Middlebury College. She is currently on the Board of Directors for the Association of Corporate Counsel Greater Philadelphia/Delaware Valley Chapter. Ms. Manogue was the 2011-2012 Chairperson of the PhRMA Law Section and was a member of the Board of Trustees of the Healthcare Institute of New Jersey (“HINJ”) from 2010-2014 and a member of HINJ’s Finance and Audit Committee from 2012-2014.
Dan A. Rudio
Daniel A. Rudio was appointed Vice President, Controller and Chief Accounting Officer effective April 1, 2011. Mr. Rudio joined the Company in November 2006 as Financial Reporting Manager and has held various positions of increasing responsibility. Prior to joining the Company, Mr. Rudio was a finance manager at Rohm and Haas Company where he worked for four years in a variety of accounting and finance positions of increasing responsibility. Mr. Rudio began his career in public accounting at Ernst & Young LLP where he worked from July 1995 to November 2002. Mr. Rudio is a licensed certified public accountant in the Commonwealth of Pennsylvania and holds Bachelors of Science degrees in both accounting and finance from Rutgers University.
Suketu “Suky” Upadhyay, Executive Vice President and Chief Financial Officer, joined Endo September 2013. Prior to joining Endo, since 2010, Mr. Upadhyay served as Interim Chief Financial Officer as well as Senior Vice President of Finance and Corporate Controller of Becton, Dickinson & Co (BD). In addition to other executive finance roles at BD, from 2007 to 2010, he served in various finance leadership roles at AstraZeneca and Johnson & Johnson. Mr. Upadhyay spent the early part of his career in public accounting with KPMG and received his CPA in May 1996. He received a Bachelor of Science in Finance from Albright College and received a Master of Business Administration from The Fuqua School of Business at Duke University.
Mark Beaudet joined Endo in March 2014 as President of Paladin Labs Inc., a specialty pharmaceutical company focused on acquiring or in-licensing innovative pharmaceutical products for Canadian and emerging markets. He is a co-founder of Paladin and served as a director as well as the company’s interim President and CEO since 2011. Prior to that, Mr. Beaudet was Vice President of Sales and Marketing for Paladin from 1996 to 2011. Prior to his work with Paladin, he held marketing management positions at Procter & Gamble Canada and Pizza Hut Canada. Mr. Beaudet also led the pharmaceutical division campaigns for Centraide of Greater Montreal from 2007 through 2013. In 2003, Mr. Beaudet was a co-recipient of the Ernst and Young Entrepreneur of the Year award in the Quebec Life Sciences Sector. He holds a B.Comm in Marketing and Entrepreneurship with Great Distinction from McGill University and is a member of the board of directors of the McGill University Health Center Foundation, the Loyola High School Foundation and Rx&D - Canada’s Research Based Pharmaceutical Industry Association.
Larry Cunningham, Executive Vice President, Human Resources, joined Endo in May 2008. In this role he leads all aspects of human resources in enabling the development and growth of Endo. Prior to joining Endo, Mr. Cunningham led Johnson & Johnson’s global recruiting and talent acquisition organization. Mr. Cunningham also has extensive business-based human resources leadership experience. He was Vice President, Human Resources, for DePuy, Inc., a wholly owned subsidiary of Johnson & Johnson, which he joined following the acquisition of Centocor, where he was Vice President, Human Resources. Prior to joining Centocor, Mr. Cunningham gained extensive domestic and international experience in human resources management and organization development at Rhone-Poulenc Rorer (now Sanofi-Aventis) and Corning Clinical Laboratories (now Quest Diagnostics). Mr. Cunningham holds a B.A. in Labor Studies from the Pennsylvania State University and a Master of Science in Business Administration from Temple University.
Blaine Davis is President, Endo Ventures and Senior Vice President, Corporate Affairs, Endo. He joined Endo in 2008. In his role as President, Endo Ventures, Mr. Davis is based in Dublin, Ireland and is responsible for guiding all aspects of Endo's International business as well as driving the expansion and growth of this business. As Senior Vice President, Corporate Affairs for Endo, he leads the company’s investor relations and corporate communications functions as well as provides strategic counsel to the executive team on the development, execution and communication of corporate strategy. Prior to joining Endo, Mr. Davis was Director of Alliance Management within the Corporate & Business Development unit at Bristol-Myers Squibb (BMS). He joined BMS in January 2005 as Director of Investor Relations. Mr. Davis began his career at Thomson Financial in New York City as Vice President of Capital Markets. He holds a Bachelor of Arts degree in Biology and Economics from Middlebury College, Vermont.
Brian Lortie is President, U.S. Branded Pharmaceuticals Business Unit. In this role he leads the fully integrated Endo Pharmaceuticals business with responsibility for all strategic, commercial, and operational functions including sales and marketing, strategy and portfolio development, commercial operations, managed markets, supply chain, and quality. He joined Endo in 2009 from GlaxoSmithKline, having served in a number of executive roles in the US and internationally, including Vice President, External Ventures; Vice President of Marketing, US; Vice President and Global Head, HPV Vaccine Franchise; and Managing Director/General Manager, Ireland. He brings to Endo an extensive track record of leadership success in all areas of the pharmaceutical business including product development, commercialization, business development and strategy. Mr. Lortie holds a Bachelor of Arts degree with honors in Biology and Psychology from Boston University and studied at the Villanova University Graduate School of Business.
Norbert Oppitz joined Endo in October 2014 as Regional President, Latin America, Africa and Export Markets. In this role, he is responsible for the expansion of Endo’s Latin American and emerging markets business leveraging the Company’s existing portfolio of assets as well as advancing new business opportunities. Prior to joining Endo, Mr. Oppitz served as Senior Vice President, Latin America for Takeda Pharmaceuticals, a role he held since 2010 when he joined Nycomed, which was subsequently acquired by Takeda. During his tenure, Norbert led a fully-integrated multi-national region including Mexico, Venezuela, and Argentina. Prior to Takeda/Nycomed, Norbert held leadership positions of increasing scope and complexity at F. Hoffman-La Roche S.A. and Sanofi SA. Mr. Oppitz has over 26 years of emerging market management experience in the pharmaceutical industry and holds a Business Administration degree from Fachhochschule Rheinland Pfalz, Mainz, Germany.
Jon Smollen, Executive Vice President and Chief Compliance Officer, joined Endo in August 2011. In this role, he is responsible for the strategic direction and operations of Endo’s corporate compliance program. Mr. Smollen previously was Vice President and Chief Compliance Officer for Siemens Healthcare USA with responsibility for its laboratory diagnostic and diagnostic imaging businesses in the U.S. Prior to Siemens, Mr. Smollen held a number of leadership positions at Wyeth including Vice President, Commercial Excellence and Compliance and Chief Privacy Officer and established several global programs to strategically address existing and emerging industry requirements. Prior to Wyeth, Mr. Smollen was an Attorney Advisor to Federal Trade Commissioner Thomas B. Leary and was in private practice in Washington, D.C. He also served as a federal judicial clerk. He holds a B.A. from Georgetown University, an M.A. in International Relations from Columbia University and a J.D. from the University of Virginia School of Law.
Hemanth J. Varghese, Ph.D.
Hemanth J. Varghese, Ph.D. joined Endo in April 2014 as Executive Vice President Corporate Development and Strategy to lead the company’s global acquisitions and integration efforts. Dr. Varghese brings to Endo a successful track record in corporate development and general management in specialty pharmaceuticals, most recently serving as the Senior Vice President and General Manager of Vision Care for Bausch & Lomb, a division of Valeant Pharmaceuticals. During his tenure with Valeant, Dr. Varghese held various senior leadership roles including Senior Vice President of Corporate Development and General Manager of Valeant's Neurology & Other business unit. Over his career he has completed more than 40 corporate transactions, leading corporate development and integration initiatives including public/private acquisitions, investments, partnerships, licenses and divestitures. Prior to joining Valeant, Dr. Varghese served in corporate development and operations leadership roles at Biovail Corporation, JovInvestment Management Inc., and Robarts Research Institute. He obtained his BSc degree with honors in Biophysics and PhD in Medical Biophysics from the University of Western Ontario and holds the Charted Financial Analyst ® designation.